| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536593 | Vaccine | 2017 | 9 Pages |
Abstract
Introducing PCV13 as part of Mongolia's national programme appears to be highly cost-effective when compared to no vaccination and cost-saving from a societal perspective at vaccine purchase prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high-quality national data would improve future economic analyses for vaccine introduction.
Keywords
DALYICERWPRIPDOOPMNTGNIAmCPCV13PAHOAOMCFRCost-effectivenessInvasive pneumococcal diseaseBudget impactGross domestic productGDPOut-of-pocketGross National Incomeacute otitis mediaPan American Health Organizationdisability-adjusted life yearWestern Pacific RegionMongoliaIncremental cost-effectiveness ratioHaemophilus influenzae type bHibVaccinePneumococcal conjugate vaccinePCV یا Pneumococcal conjugate vaccineMoHMinistry of Health
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Neisha Sundaram, Cynthia Chen, Joanne Yoong, Munkh-Erdene Luvsan, Kimberley Fox, Amarzaya Sarankhuu, Sophie La Vincente, Mark Jit,